Cyr Financial’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.68M Buy
1,448
+69
+5% +$81.4K 0.81% 20
2026
Q2
$1.65M Buy
1,379
+153
+12% +$156K 0.86% 15
2026
Q1
$1.13M Buy
1,226
+147
+14% +$149K 0.66% 33
2025
Q4
$1.16M Sell
1,079
-37
-3% -$35.4K 0.72% 26
2025
Q3
$852K Buy
1,116
+33
+3% +$24.6K 0.58% 37
2025
Q2
$844K Buy
1,083
+262
+32% +$204K 0.65% 36
2025
Q1
$678K Buy
821
+91
+12% +$75.7K 0.61% 30
2024
Q4
$564K Buy
+730
New +$604K 0.51% 39

Other funds holding LLY

Cyr Financial's LLY Position: Q3 2026 in Review

Cyr Financial increased its Eli Lilly (LLY) stake by 5% in Q3 2026, buying an estimated $81.4K and bringing the position to 1,448 shares worth $1.68M. The position accounts for 0.81% of the portfolio, ranked #20.

Cyr Financial first reported a position in LLY in Q4 2024 and has held it in 8 quarters since. 1,509 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Cyr Financial held 1,448 shares of Eli Lilly worth $1.68M as of Q3 2026.
  • Cyr Financial bought 69 Eli Lilly shares in Q3 2026, an estimated $81.4K.
  • Eli Lilly made up 0.81% of Cyr Financial's portfolio in Q3 2026, its #20 holding.
  • Cyr Financial first reported a position in Eli Lilly in Q4 2024 and has held it in 8 quarters since.
  • 1,509 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Cyr Financial's 13F filing for Q3 2026, filed 16 Oct 2026.